Jonathan Raa | Nurphoto | Getty Images
Novo Nordisk shares climbed 5% on Thursday morning, based on LSEG knowledge, hitting a recent file highs after the Danish pharmaceutical big reported optimistic early trial knowledge for a brand new experimental weight reduction drug.
The firm informed an investor assembly that the Phase I trial of its highly-anticipated weight problems drug amycretin confirmed a 13.1% weight reduction in contributors after 12 weeks, based on Reuters. This studying eclipses the 6% loss recorded after a 12-week trial for the corporate’s wildly common weight problems drug Wegovy.
A Phase II trial will start within the second half of this 12 months, with outcomes anticipated in early 2026, the corporate stated.
Shares of Novo Nordisk, Europe’s largest firm by market cap, have gained greater than 27% because the flip of the 12 months because the prescribed drugs big continues to reap the advantages of rampant demand for its flagship Wegovy and Ozempic anti-obesity medicine.
Earlier this week, Novo reported late-stage trial outcomes exhibiting that Ozempic reduce the chance of kidney illness development and demise from kidney or cardiovascular issues by 24% in diabetic sufferers with power kidney illness.
The outcomes added to mounting proof of the broader well being advantages related to Ozempic and related medicine, past weight reduction and Type 2 diabetes remedy.
Shares of American rival Eli Lilly have been down 1.3% in after hours buying and selling on the again of the information.
Source: www.cnbc.com”